| Upcoming events on VERTEX PHARMACEUTICALS |
|
| 04/29/21 | | Q1 2021 Earnings Release (Projected) |
| 07/28/21 | | Interim 2021 Earnings Release (Projected) |
| 10/27/21 | | Q3 2021 Earnings Release (Projected) |
| 02/02/22 | | FY 2021 Earnings Release (Projected) |
|
| Past events on VERTEX PHARMACEUTICALS |
|
| 02/01/21 | 04:30pm | | FY 2020 Earnings Call |
| 02/01/21 | 04:01pm | | FY 2020 Earnings Release |
| 01/11/21 | 09:10am | | JP Morgan Healthcare Conference |
| 12/09/20 | 08:00am | | CTX001™ Phase 1/2 Study Results Call |
|
| Upcoming sector events for VERTEX PHARMACEUTICALS |
|
|
| |
|
| Past sector events for VERTEX PHARMACEUTICALS |
|
|
|
|
|
| Annual results | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 (e) |
Sales
M $ |
Released
Forecast
Spread | 1 702
1 696
0,38% | 2 489
2 431
2,4% | 3 048
2 992
1,9% | 4 163
3 759
11% | 6 206
6 159
0,76% |
6 947
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 71,3
58,7
22% | 185
119
56% | 1 184
1 123
5,4% | 1 893
1 770
6,9% | 3 601
3 649
-1,3% |
4 190
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 288
278
3,8% | 564
538
4,9% | 1 112
1 052
5,7% | 1 786
1 609
11% | 3 491
3 471
0,58% |
3 846
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | -67,4
-91,9
27% | -15,7
-70,5
78% | 600
771
-22% | 1 395
964
45% | 3 117
2 891
7,8% |
3 152
|
Net income
M $ |
Released
Forecast
Spread | -112
-135
17% | 263
237
11% | 2 097
740
183% | 1 177
796
48% | 2 712
2 608
4,0% |
2 558
|
EPS
$ |
Released
Forecast
Spread | -0,46
-0,55
17% | 1,04
0,90
15% | 8,09
2,84
185% | 4,51
3,08
46% | 10,3
9,87
4,2% |
9,86
| | Announcement Date | 01/25/2017 | 01/31/2018 | 02/05/2019 | 01/30/2020 | 02/01/2021 | |
|
|
|
| Quarterly results | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) | 2022 Q1 (e) |
Sales
M $ |
Released
Forecast
Spread | 785
782
0,33% | 870
818
6,3% | 858
853
0,64% | 941
885
6,4% | 950
948
0,15% | 1 413
1 013
40% | 1 515
1 287
18% | 1 524
1 393
9,4% | 1 538
1 480
3,9% | 1 628
1 585
2,7% |
1 658
|
1 705
|
1 751
|
1 801
|
1 882
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 314
297
5,6% | 367
310
18% |
|
|
| 619
483
28% | 747
759
-1,6% | 901
875
2,9% | 881
890
-1,1% | 916
1 001
-8,5% |
1 030
|
1 060
|
1 125
|
1 135
|
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 295
285
3,6% | 348
312
12% | 377
335
12% | 413
357
16% | 403
400
0,71% | 593
429
38% | 877
628
40% | 874
725
21% | 854
797
7,2% | 887
872
1,7% |
920
|
942
|
958
|
991
|
1 002
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 137
187
-27% | 32,5
205
-84% | 320
228
40% | 327
249
31% | 70,7
199
-65% | 677
237
185% | 658
531
24% | 825
569
45% | 746
658
13% | 889
704
26% |
760
|
784
|
799
|
825
|
861
|
Net income
M $ |
Released
Forecast
Spread | 129
187
-31% | 1 551
201
671% | 269
187
44% | 267
199
34% | 57,5
189
-70% | 583
189
208% | 603
408
48% | 837
433
93% | 667
523
28% | 604
577
4,8% |
620
|
637
|
649
|
656
|
701
|
EPS
$ |
Released
Forecast
Spread | 0,50
0,71
-29% | 5,97
0,74
704% | 1,03
0,73
41% | 1,03
0,76
35% | 0,22
0,73
-70% | 2,23
0,76
194% | 2,29
1,60
43% | 3,18
1,66
91% | 2,53
1,98
28% | 2,30
2,13
8,2% |
2,28
|
2,35
|
2,39
|
2,45
|
2,62
| | Announcement Date | 10/24/2018 | 02/05/2019 | 04/30/2019 | 07/31/2019 | 10/30/2019 | 01/30/2020 | 04/29/2020 | 07/30/2020 | 10/29/2020 | 02/01/2021 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
